Pharmaceuticals 22 January 2026

AstraZeneca stock faces a new test: Iraq terrorism lawsuit revived with NYSE move days away

A U.S. appeals court on Friday revived a lawsuit accusing AstraZeneca and several major drug and medical-device companies of funneling millions in cash and medical supplies to fund terrorism in Iraq. The plaintiffs claim the firms made corrupt payments to Jaysh al‑Mahdi, a militia backed by Hezbollah, to win contracts from the Iraqi Health Ministry. They are seeking unspecified damages under the U.S. Anti‑Terrorism Act.

24 January 2026

NYSE:AZN·Pharmaceuticals·Stock Market

Novo Nordisk Class B stock heads into Monday with Wegovy pill scripts and Victoza lawsuit in focus

Novo Nordisk A/S Class B shares closed higher on Friday in Copenhagen and head into the new week on that note, boosted by early signs of strong demand for its Wegovy weight-loss drug.

24 January 2026

NASDAQ:NVO·Pharmaceuticals·Stock Market

Roche stock price holds near a 52-week high as Jan. 29 results near — what to watch next week

Roche Holding’s non-voting shares ended Friday at 348.10 Swiss francs, rising 0.20 franc. The stock hovered just shy of its 52-week peak during the session.

24 January 2026

Earnings Reports·Pharmaceuticals·Stock Market·SWX:ROG

AbbVie stock price: ABBV ends higher into weekend, with India patent setback and Feb. 4 earnings in focus

AbbVie shares closed Friday 0.53% higher at $219.26, securing a slightly stronger position ahead of the weekend shutdown of U.S. markets.

24 January 2026

Earnings Reports·NYSE:ABBV·Pharmaceuticals·Stock Market

Eli Lilly stock slips as obesity-drug headlines pile up ahead of next week

Eli Lilly and Co shares fell on Friday, breaking a brief streak of gains as investors refocused on the ongoing battle in the obesity drug sector that has driven the stock’s recent volatility. The shares closed 2.12% lower at $1,064.29.

24 January 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk

Moderna shares dropped on Friday following a volatile week, as investors absorbed the company’s caution about mounting U.S. political and regulatory challenges affecting its vaccine development funding.

24 January 2026

NASDAQ:MRNA·NYSE:MRK·Pharmaceuticals·Stock Market

Sarepta stock eyes a Monday swing as Elevidys 3-year EMBARK data gets a date

Sarepta Therapeutics Inc shares climbed in after-hours trading Friday following the announcement of a Jan. 26 update on three-year data for its Duchenne gene therapy, Elevidys. The stock had closed down 3% at $21.13 but later traded near $22.20, a roughly 5% gain.

24 January 2026

NASDAQ:SRPT·Pharmaceuticals·Stock Market

GSK share price in focus after China clears Trelegy for asthma — what to watch next week

GSK plc shares slipped 0.2% to 1,801 pence on Friday following news that China approved Trelegy Ellipta for adults with uncontrolled asthma. With London trading closed for the weekend, investors will have to wait until Monday to assess the impact of the new label.

24 January 2026

Financial Forecasts·Healthcare News·LSE:GSK·NYSE:GSK·Pharmaceuticals·Stock Market

Merck (MRK) stock price slips into the weekend — what investors watch next week

Merck & Co shares ended Friday down 0.92%, closing at $108.18. In after-hours trading, the stock slipped slightly to $107.91.

24 January 2026

NASDAQ:MRNA·NYSE:MRK·Pharmaceuticals·Stock Market

Eli Lilly stock slips after hours as obesity-pill race stays in the spotlight

Eli Lilly and Company shares dropped 2.1% on Friday, closing near $1,064.29 in after-hours trading. During the session, the stock swung between $1,094.57 and $1,063.25.

24 January 2026

Health News·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

AbbVie stock rises as India rejects Venetoclax patent bid; ABBV traders eye Feb. 4 earnings

AbbVie Inc. shares rose about 0.6% on Friday after an Indian report said the country’s patent office rejected the drugmaker’s bid to patent venetoclax, a blood-cancer treatment sold as Venclexta. The stock was up 0.6% at $219.33 in afternoon trade, even as the Health Care Select Sector SPDR Fund fell about 0.6%.

23 January 2026

Earnings Reports·NYSE:ABBV·Pharmaceuticals·Stock Market

Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer shares dropped roughly 1.9% to $25.62 Friday afternoon, underperforming the health-care sector as the stock went ex-dividend. The Health Care Select Sector SPDR Fund dipped about 0.5%, while the SPDR S&P 500 ETF Trust inched up around 0.1%. Merck slipped about 1%, and Moderna tumbled over 7%. Trading volume for Pfizer hit roughly 24.8 million shares.

23 January 2026

Earnings Reports·NASDAQ:MRNA·NYSE:MRK·NYSE:PFE·Pharmaceuticals·Stock Market

Moderna stock slides nearly 6% as CEO flags pullback in Phase III vaccine trials

Moderna shares slipped 5.8%, hitting $48.88 by midday Friday, after fluctuating between $46.86 and $50.95 earlier. Roughly 10.9 million shares traded hands.

23 January 2026

NASDAQ:MRNA·Pharmaceuticals·Stock Market

Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

Eli Lilly shares dropped Friday, rattled by investor concerns after rival Novo Nordisk’s Wegovy pill recorded over 18,000 U.S. prescriptions in its first full week on shelves.

23 January 2026

Earnings Reports·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Johnson & Johnson stock today: Why JNJ can’t break out as talc risk shadows upbeat 2026 outlook

Johnson & Johnson shares barely moved on Friday, edging up less than 0.1% to $218.59 by 11:01 a.m. EST. Upgrades from Wall Street clashed with renewed concerns over the company’s ongoing talc litigation.

23 January 2026

NYSE:JNJ·Pharmaceuticals·Stock Market

60 Degrees Pharmaceuticals stock swings again: SXTP slides in premarket after Runway Health deal pop

Shares of 60 Degrees Pharmaceuticals slipped 9.9% to $4.54 in premarket action on Friday, following a wild session the day before where the stock soared 152% to close at $5.04. Thursday saw the share price swing between $4.40 and $8.62, with trading volume hitting roughly 196 million shares.

23 January 2026

NASDAQ:SXTP·Pharmaceuticals·Stock Market

India’s Q3 results rush: IndusInd Bank profit seen plunging as JSW Steel, BPCL, Cipla report today

Friday’s earnings slate in India is packed, with more than 50 firms set to report their December 2025 quarter results. IndusInd Bank stands out, expected to post a significant profit decline, based on brokerage forecasts.

23 January 2026

Earnings Reports·NSE:BPCL·NSE:CIPLA·NSE:INDUSINDBK·NSE:JSWSTEEL·Pharmaceuticals·Stock Market

Pfizer stock ticks up as ViiV exit plan and Novavax vaccine deal keep PFE in focus

Pfizer shares climbed Thursday after the company announced two deals highlighting its strategy to transform its business. By afternoon, the stock had gained roughly 0.8%, reaching $26.10.

22 January 2026

LSE:GSK·NASDAQ:NVAX·NYSE:PFE·Pfizer·Pharmaceuticals·Stock Market

Eli Lilly stock price today: LLY edges up after FDA “breakthrough” tag as Feb. 4 earnings near

Eli Lilly shares edged up 0.3% to $1,081.59 on Thursday, fluctuating between $1,072.46 and $1,095.15 earlier in the session.

22 January 2026

Earnings Reports·NYSE:LLY·Pharmaceuticals·Stock Market

60 Degrees Pharmaceuticals (SXTP) stock more than triples as Runway Health deal hits tape

Shares of 60 Degrees Pharmaceuticals, Inc. surged over 267% Thursday, hitting $7.34 by 9:57 a.m. EST. The stock had closed Wednesday at $2.00 and traded between $5.99 and $8.62 earlier today.

22 January 2026

NASDAQ:SXTP·Pharmaceuticals

Pharmaceuticals 22 January 2026 - 24 January 2026